Programmed cell death in cancer cells;Programovaná buněčná smrt v nádorových buňkách

Klinicka Onkologie

Volumn 27, Issue SUPPL. 1, 2014, Pages

  Ondroušková, Eva ^a   Vojtesek B ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Apoptosis; Autophagy; Bcl 2; Caspases; Necroptosis; Programmed cell death

Indexed keywords

DEATH RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER GENETICS; CANCER THERAPY; CELL DEATH; GENE MUTATION; MALIGNANT TRANSFORMATION; NECROPTOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; CELL TRANSFORMATION; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

CELL DEATH; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84903521837     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: 10.14735/amko20141S7     Document Type: Review

References (93)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-674. doi: 10.1016/j.cell.2011.02.013.
2. Kroemer G, Galluzzi L, Vandenabeele P et al. Classification of cell death: recommendation of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16(1): 3-11. doi: 10.1038/cdd.2008.150.
3. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26(4): 239-257.
4. Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol 2005; 6(4): 328-340. (Pubitemid 40516899)
5. Rubinstein AD, Kimchi A. Life in the balance - a mechanistic view of the crosstalk between autophagy and apoptosis. J Cell Sci 2012; 125(Pt 22): 5259-5268. doi: 10.1242/jcs.115865.
6. Martinet W, Schrijvers DM, Herman AG et al. Z-VAD-fmk induced non-apoptotic cell death of macrophages. Autophagy 2006; 2(4): 312-314.
7. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73(8): 2013-2026. (Pubitemid 24107952)
8. Fadok VA, Bratton DL, Frasch SC et al. The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death Differ 1998; 5(7): 551-562. (Pubitemid 28356576)
9. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281(5381): 1305-1308. (Pubitemid 28406815)
10. Wachman K, Pop C, van Raam BJ et al. Activation and specifity of human caspase-10. Biochemistry 2010; 49(38): 8307-8315. doi: 10.1021/bi100968m.
11. Michalak EM, Villunger A, Adams JM et al. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ 2008; 15(6): 1019-1029. doi: 10.1038/cdd.2008.16. (Pubitemid 351712606)
12. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011; 223(2): 116-126. doi: 10.1002/path.2784.
13. Amaral JD, Xavier JM, Steer CJ et al. The role of p53 in apoptosis. Discov Med 2010; 9(45): 145-152.
14. Burlacu A, Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med 2003; 7(3): 249-257. (Pubitemid 37372044)
15. Chipuk JE, Kuwana T, Bouchier-Hayes L et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303(5660): 1010-1014. (Pubitemid 38209704)
16. Chipuk JE, Moldoveanu T, Llambi F et al.The Bcl-2 family reunion. Molecular Cell 2010; 37(3): 299-310. doi: 10.1016/j.molcel.2010.01.025.
17. Sedlak TW, Oltvai ZN, Yang E et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax Proc Natl Acad Sci USA 1995; 92(17): 7834-7838.
18. Vela L, Gonzalo O, Naval J et al. Direct interaction of Bax and Bak proteins with Bcl-2 homology domain 3 (BH3)-only proteins in living cells revealed by fluorescence complementation. J Biol Chem 2013; 288(7): 4935-4946. doi: 10.1074/jbc.M112.422204.
19. Kluck RM, Bossy-Wetzel E, Green DR et at. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 1997; 275(5303): 1132-1136. (Pubitemid 27097313)
20. Zou H, Henzel WJ, Liu A et al. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90(3): 405-413. (Pubitemid 27347231)
21. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1999; 13(3): 239-252. (Pubitemid 29095796)
22. Du C, Fang M, Li Y et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102(1): 33-42.
23. Gottfried Y, Rotem A, Lotan R et al. The mitochondrial ARTS protein promotes apoptosis through targeting XIAP. EMBO J 2004; 23(7): 1627-1635. (Pubitemid 38579523)
24. Schafer P, Scholz SR, Gimadutdinow O et al. Structural and functional characterization of mitochondrial EndoG, a sugar non-specific nuclease which plays an important role during apoptosis. J Mol Biol 2004; 338(2): 217-228. (Pubitemid 38447081)
25. Nakagawa T, Zhu H, Morishima N et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000; 403(6765): 98-103. (Pubitemid 30038529)
26. Beneš P, Větvička V, Fusek M. Cathepsin D - many functions of one aspartic protease. Crit Rev Oncol Hematol 2008; 68(1): 12-28. doi: 10.1016/j.critrevonc.2008.02.008.
27. Guicciardi ME, Leist M, Gores GJ. Lysosomes in cell death. Oncogene 2004; 23(16): 2881-2890. (Pubitemid 38638850)
28. Fisher U, Janicke RU, Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 2003; 10(1): 76-100. (Pubitemid 36511834)
29. de Duve CH, Wattiaux R. Functions of lysosome. Annu Rev Physiol 1966; 28: 435-492.
30. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011; 147(4): 728-741. doi: 10.1016/j.cell.2011.10.026.
31. Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. Nat Cell Biol 2010; 12(9): 814-822. doi: 10.1038/ncb0910-814.
32. Rosenfeldt MT, Ryan KM. The multiple roles of autophagy in cancer. Carcinogenesis 2011; 32(7): 955-963. doi: 10.1093/carcin/bgr031.
33. Esposti DD, Domart MC, Sebagh M et al. Autophagy is induced by ischemic preconditioning in human livers formerly treated by chemotherapy to limit necrosis. Autophagy 2010; 6(1): 172-174.
34. Mathew R, Kongara S, Beaudoin B et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev 2007; 21 (11): 1367-1381. (Pubitemid 46871040)
35. Yang S, Wang X, Contino G et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011; 25(7): 717-729. doi: 10.1101/gad.2016111.
36. Levine B, Yuan J. Autophagy in cell death: an innocent convict? J Clin Invest 2005; 115(10): 2679-2688. (Pubitemid 41434392)
37. Berry DL, Baehrecke EH. Growth arrest and autophagy are required for salivary gland cell degradation in Drosophila. Cell 2007; 131(6): 1137-1148. (Pubitemid 350235023)
38. Degterev A, Huang Z, Boyce M et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1(2): 112-119.
39. Vanlangenakker N, Bertrand MJM, Bogaert P et al. TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and II members. Cell Death Dis 2011; 2(11): e230. doi: 10.1038/cddis.2011.111.
40. Scaffidi C, Kirchhoff S, Krammer PH et al. Apoptosis signaling in lymphocytes. Curr Opin Immunol 1999; 11 (3): 277-285.
41. Degterev A, Hitomi J, Germscheid M et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4(5): 313-321. doi: 10.1038/nchembio.83. (Pubitemid 351550892)
42. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008: 132(3): 344-362. doi: 10.1016/j.cell.2008.01.020.
43. Ouyang L, Shi Z, Zhao S et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif 2012; 45(6): 478-498. doi: 10.1111/j.1365-2184.2012.00845.x.
44. Zhang DW, Shao J, Lin J et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009; 325(5938): 332-336. doi: 10.1126/science.1172308.
45. Lin Y, Choksi S, Shen HM et al. Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. J Biol Chem 2004; 279(11): 10822-10828. (Pubitemid 38372695)
46. Vandenabeele P, Galluzzi L, Vanden BergheT et al. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11(10): 700-714. doi: 10.1038/nrm2970.
47. Natoli G, Ianni A, Constanzo A et al. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995; 11(6): 1157-1164.
48. Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388(6638): 190-195. (Pubitemid 27297457)
49. Rieux-Laucat F, Le Deist F, Hivroz C et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimunity. Science 1995; 268(5215): 1347-1349.
50. Landowsky TH, Qu N, Buyuksal I et al. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997; 90(11): 4266-4270. (Pubitemid 27508431)
51. Gronbaek K, Straten PT, Ralfkiaer E et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998; 92(9): 3018-3024. (Pubitemid 28492305)
52. Bin L, Thorburn J, Thomas LR et al. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J Biol Chem 2007; 282(38): 28189-28194. (Pubitemid 47529548)
53. Lee SH, Shin MS, Kim HS et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 1999; 59(22): 5683-5686.
54. Shin MS, Kim HS, Lee SH et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001; 61 (13): 4942-4946.
55. Fisher MJ, Virmani LW, Aplenc R et al. Nucleotide substitution in the ectodomain of TRAIL receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res; 7(6): 1688-1697.
56. Tsujimoto Y, Gorham J, Cossman J et al. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985; 229(4720): 1390-1393. (Pubitemid 16222379)
57. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011; 18(9): 1414-1424. doi: 10.1038/cdd.2011.17.
58. Krajewski S, Krajewska M, Shabaik A et al. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 1994; 54(21): 5501-5507. (Pubitemid 24346233)
59. Beroukhim R, Mermel C, Porter D et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463(7283): 899-905. doi: 10.1038/nature08822.
60. Tagawa H, Karnan S, Suzuki R et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005; 24(8): 1348-1358. (Pubitemid 40343115)
61. Garrison SP, Jeffers JR, Yang C et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol 2008; 28(17): 5391-5402. doi: 10.1128/MCB.00907-07.
62. Rampino N, Yamamoto H, Ionov Y et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275(5302): 967-969. (Pubitemid 27087710)
63. Meijerink JP, Smetsers TF, Sloetjes AW et al. Bax mutations in cell lines derived from hematological malignancies. Leukemia 1995; 9(11): 1828-1832.
64. Soengas MS, Capoieci P, Polsky D et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409(6817): 207-211. (Pubitemid 32144287)
65. Sturm I, Bosanquet AG, Radetzki S et al. Silencing of Apaf-1 in B-CLL results in poor prognosis in the case of concomitant p53 mutation. Int J Cancer 2006; 118(9): 2329-2336.
66. Dubrez L, Berthelet J, Glorian V. IAP proteins as target for drug development in oncology. Onco Targets Ther 2013;6:1285-1304.
67. Garrison JB, Samuel T, Reed JC. TRAF2-binding BIR1 domain of C-IAP2/MALT1 fusion protein is essential for activation of NF-kappaB. Oncogene 2009; 28(13): 1584-1593. doi: 10.1038/onc.2009.17.
68. Annunziata CM, Davis RE, Demchenko Y et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12(2): 115-130. (Pubitemid 47199123)
69. Filipovich AH, Zhang K, Snow AL et al. X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood 2010; 116(18): 3398-3408. doi: 10.1182/blood-2010-03-275909.
70. Soung YH, Lee JW, Kim SY et al. Caspase-8 gene is inactivated by somatic mutations in gastric carcinomac Cancer Res 2005; 65(3): 815-821.
71. Martinez R, Setien F, Voelter C et al. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis 2007; 28(6): 1264-1268. (Pubitemid 47062686)
72. Soung YH, Lee JW, Kim SY et al. Somatic mutations of CASP3 gene in human cancers. Hum Genet 2004; 115(2): 112-115. (Pubitemid 39010925)
73. Soung YH, Lee JW, Kim HS et al. Inactivating mutations of CASPASE-7 gene in human cancers. Oncogene 2003; 22(39): 8048-8052. (Pubitemid 37175869)
74. Chen K, Zhao H, Hu Z et al. CASP3 polymorphisms and risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 2008; 14(19): 6343-6349. doi: 10.1158/1078-0432.CCR-08-1198.
75. Olsson M, Zhivotovsky B. Caspases and cancer. Cell Death Differ 2011; 18(9): 1441-1449. doi: 10.1038/cdd.2011.30.
76. Greco FA, Bonomi P, Crawford J et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1 in patients with advanced non-small cell lung cancer. Lung Cancer 2008; 61(1): 82-90. doi: 10.1016/j.lungcan.2007.12.011.
77. Zhang I, Zhang X, Barrisford GE et al. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 2007; 251 (1): 146-157. (Pubitemid 46589773)
78. Zinonos I, Labrinidis A, Lee M et al. Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Mol Cancer Ther 2009; 8(10): 2969-2980. doi: 10.1158/1535-7163.MCT-09-0745.
79. Soria JC, Mark Z, Zatloukal P et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small cell lung cancer. J Clin Oncol 2011; 29(33): 4442-4451. doi: 10.1200/JCO.2011.37.2623.
80. Jia LT, Zhang LH, Yu CJ et al. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res 2003; 63(12): 3257-3262.
81. Shariat SF, Desai S, Song W et al. Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer. Cancer Res 2001; 61(6): 2562-2571. (Pubitemid 32685840)
82. Tanioka M, Nokihara H, Yamamoto N et al. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 68(2): 505-511. doi: 10.1007/s00280-010-1506-7.
83. Schimmer AD, Estey EH, Borthakur G et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009; 27(28): 4741-4746. doi: 10.1200/JCO.2009.21.8172.
84. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer. Nat Rev Cancer 2010; 10(8): 561-574. doi: 10.1038//nrc2889.
85. Qin Q, Zuo Y, Yang X et al. Smac mimetic compound LCL161 sensitizes esophageal carcinoma cells to radiotherapy by inhibiting the expression of inhibitor of apoptosis protein. Tumor Biol 2014; 35(3): 2565-2574. doi: 10.1007/s13277-013-1338-2.
86. O'Brien S, Moore JO, Boyd TE et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009; 27(31): 5208-5212. doi: 10.1200/JCO.2009.22.5748.
87. Goard CA, Schimmer AD. An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evid 2013; 8:15-26. doi: 10.2147/CE.S42568.
88. Baggstrom MQ, Qi Y, Koczywas M et al. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol 2011; 6(10): 1757-1760. doi: 10.1097/JTO. 0b013e31822e2941.
89. Rudin CM, Hann CL, Garon EB et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012; 18(11): 3163-3169. doi: 10.1158/1078-0432.CCR-11-3090.
90. Chaabane W, User SD, El-Gazzah M et al. Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer. Arch Immunol Ther Exp 2013; 61(1): 43-58. doi: 10.1007/s00005-012-0205-y.
91. Ondroušková E, Souček K, Horváth V et al. Alternative pathways of programmed cell death are activated in cells with defective caspase-dependent apoptosis. Leuk Res 2008; 32(4): 599-609. (Pubitemid 351248952)
92. Walker NI, Harmon BV, Gobé GC et al. Patterns of cell death. Methods Achiev Exp Pathol 1988; 13:18-54.
93. Brown M, Wilson G. Apoptosis genes and resistance to cancer therapy. Cancer Biol Ther 2003; 2(5): 477-490.